Spots Global Cancer Trial Database for Haplo-SCT vs ASCT With or Without Decitabine in AML CR1
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Haplo-SCT vs ASCT With or Without Decitabine in AML CR1
Official Title: Haplo-mismatch Donor Stem Cell Transplantation (SCT) Versus Autologous SCT Followed or Not by Maintenance Therapy, for Patients With Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study
Study ID: NCT02059720
Conditions
Interventions
Study Description
Brief Summary: A multicentre, prospective, open-label clinical study, including a randomized controlled study in low or intermediate-risk group patients, and a cohort study of maintenance treatment with decitabine after ASCT.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Fisrt Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Contact Details
Name: Depei Wu, M.D., Ph.D.
Affiliation: The First Affiliated Hospital of Soochow University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
